12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ADXS-HPV: Completed Phase II enrollment

Advaxis completed enrollment of 110 women with recurrent or refractory cervical cancer in an Indian Phase II trial evaluating IV ADXS-HPV with or without cisplatin. In January, Advaxis...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >